Podcasts about idera

Host Dr. Shannon Westin and guest Dr. Hani Babiker discuss the JCO article "Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study." TRANSCRIPT TTFields in Locally Advanced Pancreatic Adenocarcinoma Dr. Shannon Westin: Hello everyone, and welcome to another episode of JCO After Hours, the podcast where we get in depth with manuscripts that have been published in the Journal of Clinical Oncology. I am your host, gynecologic oncologist Shannon Westin, social media editor at the JCO, and just excited to be here to learn today about pancreatic cancer. None of our participants have conflicts of interest related to this podcast, and it is my honor to introduce Dr. Hani Babiker. He is an associate professor of medicine, consultant in oncology at the Mayo Clinic in Jacksonville, Florida. Welcome, Dr. Babiker. Dr. Hani Babiker: Hi, Dr. Westin. Thank you for the great opportunity to discuss our trial, and thank you for having me here. I really appreciate it, and I am excited. Dr. Shannon Westin: All right, so are we. So we are going to be talking about “Tumor Treating Fields with Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: A Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study.” This was simultaneously published and presented in the JCO and at the annual meeting of ASCO on 5/31/2025. So, let's level set. Can you speak to us just a little bit about pancreatic cancer? What is the survival, and what is the typical treatment for locally advanced disease? This gynecologic oncologist has not kept up in this field. Dr. Hani Babiker: Absolutely, Dr. Westin, and thank you for that question. Pancreatic adenocarcinoma is a lethal cancer. When I first started my career, the 5-year survival, per the Surveillance, Epidemiology, and End Results, was at 4.5%. I always, whenever I was giving talks, say that I really hope that I will see it in the double digit. Now, the 5-year survival for all pancreatic adenocarcinoma is 13.3%. And the 5-year survival, and although it is a double digit, I still hope that I will see it in a higher double digit in the future. It is even worse in patients with metastatic cancer, about 3% 5-year survival for metastatic pancreatic cancer. It is a dismal diagnosis. I really hope in the future we will find a better therapeutic approach to this lethal cancer. Dr. Shannon Westin: Yes, I just lost a very dear friend and colleague to this disease, so I completely agree with you. Well, now that we are settled kind of with the basics here, I would love to talk a little bit about kind of the primary piece of this intervention, the Tumor Treating Fields. So, how does this work? And what diseases has it gotten indications in as yet? Dr. Hani Babiker: Absolutely. So, Tumor Treating Fields is alternating frequency electrical fields that have been studied preclinically and shown that it abrogates cancer cell proliferation. Earlier on, we knew that it inhibits polymerization of tubulin, and hence, it affects cancer cells from proliferating. Later, we are learning that there are multiple mechanisms of action. It affects permeability, allowing for better drug delivery. It also inhibits cancer cell proliferation through affecting autophagy mechanisms that pancreatic cancer cells will use for proliferating and becoming more aggressive. There is also some early data preclinically in colorectal cancer cell lines and lung cancer cell lines and in vivo models showing that it potentially could activate the microenvironment to make it more pro-immunogenic. We recently published papers showing that it could also affect the nanomechanical properties of the tumor microenvironment within pancreatic cancer, hinting towards affecting, potentially, the stroma. So, there are multiple mechanisms to Tumor Treating Electric Fields. It is a new, novel therapeutic approach. Sometimes when I speak with my trainees, I say, "Well, we have surgery, we have radiation and chemotherapy, and this is something new." Tumor Treating Fields initially was studied in refractory GBM and got an indication there. Subsequently, frontline treatment of GBM in a randomized clinical trial, and then malignant pleural mesothelioma and non-small cell lung cancer. We have studied it in pancreatic cancer. Dr. Shannon Westin: I don't think I have ever heard it described so perfectly. That was brilliant. So thank you, and I hope everyone listening knows that you just got a masterclass on this mechanism. You know, they dabbled in it a little bit in ovarian cancer and it didn't quite make the grade, so I was a little definitely disappointed. But very excited about the data we're going to talk about today. So let's get into the PANOVA-3 study. Can you highlight the overall design and also the key eligibility criteria that would be helpful for our listeners? Dr. Hani Babiker: Absolutely. So, it started off with preclinical work in pancreatic cancer showing Tumor Treating Fields with chemo abrogate cancer cell perforation. It led to a trial, the PANOVA-2 trial, that was run in Europe that showed efficacy for OS and PFS in patients with locally advanced pancreatic cancer, which included metastatic and locally advanced pancreatic cancer, more so in locally advanced that led to the PANOVA-3 trial, which was an international, global study. This was in more than 190 centers, 20 countries in Latin America, North America, Europe, and Asia. It was a randomized trial. Patients were randomized 1 to 1 to either chemotherapy with gemcitabine plus nab-paclitaxel per drug label. The other arm was with Tumor Treating Fields at 150 kHz for a recommendation for patients to wear it 18 hours per day. The primary end point of the trial was OS, overall survival. The secondary end point included other efficacy landmarks such as local PFS, pain control, quality of life, and safety. And there was a post hoc that looked at distant PFS. Dr. Shannon Westin: That's a pretty common secondary end point in pancreatic studies of looking at the pain-free interval. I thought that was really brilliant because, you know, I think in gyn cancers, we see resolution of symptoms as being a really big deal, but it's not necessarily something that we always look at. So I thought that was really nice that you included that. Okay, talk to us a little bit about the population. So, the population that actually got treated in PANOVA-3 is pretty generalizable to what people are treating in the clinic. Dr. Hani Babiker: So, in pancreatic cancer, unfortunately, most of our patients present, approximately 80%, with metastatic disease. Local is divided to resectable, borderline, and locally advanced. We studied this trial, a randomized trial, in locally advanced and unresectable, which is really an unmet need. Most of our patients with locally advanced and unresectable are grouped up with other trials in the metastatic setting without a focus on locally advanced and unresectable, save for a few trials. This year, a trial that we were looking for for a long time, the LAPLACE trial, unfortunately, that we were very excited about, this is a molecule that targeted connective tissue growth factor, that showed earlier efficacy in a randomized trial, did not meet up the median OS end point. And hence, PANOVA-3 is the first trial in locally advanced and unresectable that did meet its primary end point. So, it's a very unmet need in locally advanced and unresectable. A lot of the times, our patients in clinic are treated with frontline chemotherapy that was studied in metastatic disease and locally advanced and unresectable, which include either FOLFIRINOX, NALIRIFOX, or gemcitabine/abraxane. I do have in my clinic multiple patients that would stay on the regimen for such a long time, and then we would have to devise a mechanism of maintenance, although this is not studied really in details, either with capecitabine or dropping the oxaliplatin to continue FOLFIRI. And then we also approach chemoradiotherapy. So the trial was in a disease in pancreatic cancer that really is an unmet need. So the inclusion criteria included a patient with locally advanced and unresectable. These were done at multiple centers. Most of them academic centers were discussed at the tumor board, and if it's unresectable, they will be meeting specific metrics of appropriate liver function tests, kidney function tests, and blood counts. We excluded patients that obviously had, given that these are electric fields, patients that have, for example, stimulators or pacemakers, knowing that this could potentially affect some of these devices. But for the most part, it was locally advanced and unresectable patients with a very good performance status and good counts. Dr. Shannon Westin: That's great. I think everyone's excited to hear about the primary outcome of overall survival. What did you find, and how does it compare to some of the recent trials? Dr. Hani Babiker: We're very excited that it did meet its primary end point of median overall survival. It was very exciting knowing that a lot of us were disappointed a little bit of some of the trials that were presented at ASCO GI, such as the LAPLACE trial that I alluded to. Just before the presentation, the PRODIGE 29 trial that is in locally advanced and unresectable that randomized patients with locally advanced disease to either FOLFIRINOX or single-agent gemcitabine, allowing for a crossover, although it did meet its primary end point of PFS, there was no overall survival benefit. So that kind of got us a little bit disappointed, but having the PANOVA-3 trial being positive in median OS got us all excited. In addition, the 12-year overall survival rate was increased in both the intention-to-treat and modified intention-to-treat. The modified intention-to-treat were patients that have had at least one cycle of therapy with TTFields daily and/or one cycle with chemotherapy, which was gemcitabine plus nab-paclitaxel. There was a trend to improvement in PFS and local PFS, although that did not have statistical significance, but the 12-year PFS rate in both the intention-to-treat and modified intention-to-treat was significant. For me, as one of the investigators, that told me that there might be a specific biomarker that would tell me that patients could respond greater than others, more exceptional than others, given that 12-month PFS rate was improved. On a post hoc analysis, the distant PFS was improved with the intervention of Tumor Treating Fields with gemcitabine plus nab-paclitaxel. In addition, there was an improvement in global health status and quality of life in addition to pain-free survival, which is a strong hurdle in our patients with pancreatic adenocarcinoma that most present with significant abdominal pain. Dr. Shannon Westin: One of the other questions that I think has come up is around central review. So did you all use central review in this study? Dr. Hani Babiker: Most of the centers were academic centers. These were discussed in tumor boards, which included radiation oncologists and surgeons. I wanted to point out that it's very important to note that the primary end point was overall survival. So the primary end point was not PFS. Hence, the central review would help us, for example, with elaborating and making sure patients were actually locally advanced disease, but in a setting where the primary end point is overall survival, that was the key point of the clinical trial. This trial was discussed at academic centers, and all included tumor boards to decide if patients were locally advanced or not. In the trial, there was a good proportion of patients, or percentage, that had a CA 19-9 more than 1000. That could indicate that potentially there are a fraction of patients that actually had metastatic disease, micrometastatic disease. So that could hint towards why the median OS was slightly lower then in both arms when compared to, for example, the trial that was presented at ASCO GI, the LAPLACE trial. However, having said that, we were very excited about the trial. It was the first positive trial in locally advanced and unresectable to meet median OS survival. Dr. Shannon Westin: It's so awesome. So congratulations. Okay, so let's talk a little bit about your very detailed secondary end points because you had a lot of really prudent choices there. So anything that was interesting or informative in those end points? Dr. Hani Babiker: One major hurdle back we have for most of our patients with pancreatic adenocarcinoma, like I mentioned earlier, is pain. We try to approach it, obviously, with narcotics. If it doesn't work, we try to do celiac axis block interventionally, and that sometimes is successful and sometimes is not. So actually, to see the pain-free survival end point to be met was very exciting for us. And as for me, as a scientist that studies TTFields in clinic and lab as also to develop a mechanism and understanding really how that works. That was very important for us that in addition to chemotherapy, it improved pain-free survival or deterioration of pain. And most importantly, our patients with pancreatic cancer, this disease is very aggressive. It affects quality of life of patients. Patients feel fatigued, tired. It's a procoagulant tumor that causes clots and strokes, etcetera, marantic endocarditis. And one big problem we deal with when we're seeing patients in clinic is obviously that quality of life. Although data have shown with treatment, with frontline regimens, that quality of life improves with treatment and chemotherapy, it's actually great to see that that improvement happens early in addition to Tumor Treating Fields. The other interesting point was that it was not only pain and quality of life, but also digestive symptoms that are improved with this intervention, knowing that a lot of our patients do have pancreatic cancer, pancreatic exocrine insufficiency that affect also with digestion, and a lot of our patients have abdominal pain after eating and diarrhea. So it was interesting to see that also improved with the intervention. Dr. Shannon Westin: You have touched a little bit on some of the adverse events, kind of with the TT mechanisms, but I'd love to hear a little bit more detail around adverse events in general in this study, as well as specific AEs related to the Tumor Treating Fields. Dr. Hani Babiker: Absolutely. So when we compared both arms, there was a similar toxicity related to the regimen, mostly with chemotherapy, but in specifically to Tumor Treating Fields, there was a rash, and that included dermatitis and rash. Most of the side effects were grade 1 and grade 2. Grade 3 toxicities related to skin was less than 10%, approximately 7% to 8%, and hence did not affect many patients. But it was something to note, and it's something that in the future, when we develop a mechanism of treating patients to note early. We in our clinic have learned to treat patients in the clinical trial early with topical steroids to each patient, of shifting the arrays to mitigate some toxicity and rash. We do advise our patients in hot areas, we keep them aware that sweating, for example, can lead to higher conductivity of electrical fields with a predisposition for rash. So if there's an opportunity to stay in a little bit of a cold area, make sure that the arrays are shifted, use topical steroids early. If it's a significant rash, to hold treatment for at least 48 hours and speak to the investigators. And through these mechanisms, we have learned that we were able to mitigate the rash quite a bit. Dr. Shannon Westin: That's awesome. Thank you so much. Yeah, I'm, it's summer right now, and I think- I'm in Texas, you're in Florida, like we know. Okay, so I guess, again, you have been kind of touching on this, but I would love to know, like if in the quality-of-life assessments or if just in your discussions with patients, like how easy is this to use? How easy is the Tumor Treating Fields device to use, and what do patients really think? Dr. Hani Babiker: Absolutely. We have learned that whenever we speak with patients, it's always good to discuss with them briefly the science of it. A lot of patients would want to know if it's interventional, is that something that goes, is delivered percutaneously or not, and we explain that these are delivered through arrays that are through the skin. We always touch base with them about a lot of question I get about mechanism of action and then about compliance. So I think one important thing to note is that compliance with the use of the device is a lot of the question we'll get quite a bit. Patients know there's going to take an effort from them, and some of my patients enjoyed it because they felt like they also are fighting the disease by wearing the device. I have learned very quickly that having a team, surrounded by a team that knew how to mitigate some of the side effects and knew how to explain how to use the device helped quite a bit. And this included some of our nurses and our nurse practitioners and our clinical research coordinators who've done a wonderful job of showing these arrays actually to patients before they start on the trial, look at it, know how it works. The other point to know is that the sponsor provided Device Support Specialist, we call them DSS, they have been instrumental in helping us, helping the patients know how to use the device, how to use the generator, how to change the batteries, and that helped us conduct the trials and enroll very well. I would envision in the future with education and relying on the Device Support Specialist and having a team that knows how to use the device and mitigate some of the side effects will go a long way for patients to learn about this treatment. Many of the times our patients said while they are on the clinical trial felt like they are also being part of this team in applying the device and fighting the cancer. Dr. Shannon Westin: That's awesome. Well, I guess the bottom line. Is it ready for prime time? Is this something you are going to use for your patients in the clinic? Dr. Hani Babiker: Absolutely. In a disease that has poor prognosis, and we are trying our best to find new treatments to fight this cancer and treatment modalities, presenting patients with all the treatment options that are out there would be recommended. It's what I would do it for in my clinic. And you know, it's funny that I am mentioning that right now. I had a patient who was seen internationally asking about the trial and the device and had locally advanced and unresectable before they start frontline treatment. I do think that there is going to be an educational piece. Obviously, this is not a pill, it's not an intravenous chemotherapy that we're very well and accustomed to. And some of us in academic centers know it very well. I usually joke that whenever I am talking about it in pancreatic cancer, if there is a radiation oncologist in the room, they will be like, "Yeah, we know all about it. We have been treating patients with GBM over there." So a lot of the times, when we first went to trial, if I had any questions, I would call them and ask them. So from their perspective, they, because they use it as a standard of care in treatment of GBM, they develop significant expertise in it. I think in the GI world, specifically and with oncologists that treat pancreatic cancer and specifically oncologists in the community, learning about the device and how to use it, how to recommend it, how to mitigate side effects, will be hopefully for prime time in the future. Dr. Shannon Westin: That's great. Sounds like some real educational opportunities there. Well, this has been awesome. Thank you so much, Dr. Babiker. I mean, I learned a ton, and I wish that we could find a way to use this in gynecologic cancers, but really, really just want to commend you on the design of the trial and the success in this really devastating disease. So again, this was "Tumor Treating Fields with Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: A Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study." And as always, I am your host, Shannon Westin. Please go check out our other offerings wherever you get your podcasts and have an awesome day. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Dr. Babiker Disclosures Consulting or Advisory Role: Endocyte, Celgene, Idera, Myovant Sciences, Novocure, Ipsen, Caris MPI, Incyte, Guardant Health Speakers' Bureau: Guardant Health Research Funding:  Spirita Oncology, Novocure, AstraZeneca, JSI, Incyte, Qurient, HiFiBiO Therapeutics, Revolution Health Care, Elevation Oncology, Dragonfly Therapeutics, Zelbio, BMS, Mirati Therapeutics, Strategia        

In some industries, artificial intelligence seems cause for optimism – not alarm – according to a recent report done by Idera that looks at the impact of AI on Quality. Judy Bossi, VP of Product Management at Idera, explains how AI is reshaping the future of QA, common barriers to AI adoption, and what's needed to move forward with new technology. Image courtesy of Idera

Steve Young a Partner, the Chairman and Co-founder of HGGC Steve is a Partner, the Chairman and Co-founder of HGGC. Steve is a member of HGGC's Management Committee, Investment Committee and Valuation Committee. He serves as Chairman of the Board of three HGGC portfolio companies: IDERA, Integrity and AutoAlert. Prior to their sales, he also served as a member of the Board of Directors for the firm's exited investments in hybris Software, Dealer-FX, Serena Software and Sunquest Information Systems. Prior to the inception of HGGC, Steve's professional football career spanned more than fifteen years in the NFL, primarily with the San Francisco 49ers, where he received numerous accolades, including Most Valuable Player of Super Bowl XXIX, Sports Illustrated and Sporting News' Player of the Year from 1992 - 1994 and the NFL's Most Valuable Player for 1992 and 1994. In 2005, Steve was inducted into the Pro Football Hall of Fame, the first left-handed quarterback to be so honored. When he retired, Steve was the highest-rated quarterback in NFL history and has the distinction of being the only signal caller in league annals to win four consecutive NFL passing titles. Steve founded and chairs the Forever Young Foundation which is actively involved in children's charities worldwide and is currently the broadcast host as well as the former International Spokesperson for the Children's Miracle Network, which has raised over one billion dollars world-wide to benefit children's hospitals.

Steve Young - NFL MVP quarterback and author Let's assume for a minute that you've just landed your dream job–your new employer is a household name, your title is the envy of thousands, and of course, you're well-paid. But what would you do if you found yourself miserable with your new situation? Our guest today faced that very situation. But through some soul-searching, and a life-changing conversation on a flight, he found his path forward–and also discovered a few things about life, love, and football. He'll help us consider the question:   How can we become more selfless leaders? A conversation with former NFL MVP quarterback and author Steve Young, on this episode of Lead With a Question. Guest Bio: Steve Young is the President and Co-Founder of HGGC, and a Director of Pathfinder Acquisition Corp. Steve serves as Chairman of the Board of four HGGC portfolio companies: IDERA, Integrity, Dealer-FX and AutoAlert. Prior to their sales, he also served as a member of the Board of Directors for the firm's exited investments in hybris Software (acquired by SAP AG (NYSE: SAP)), Serena Software (acquired by Micro Focus International plc (NYSE: MFGP)) and Sunquest Information Systems (acquired by Roper Technologies (NYSE: ROP)). Prior to the inception of HGGC, Steve's professional football career spanned more than 15 years in the NFL, primarily with the San Francisco 49ers, where he received numerous accolades, including Most Valuable Player of Super Bowl XXIX, Sports Illustrated and Sporting News' Player of the Year from 1992 - 1994 and the NFL's Most Valuable Player for 1992 and 1994. In 2005, Steve was inducted into the Pro Football Hall of Fame, the first left-handed quarterback to be so honored. When he retired, Steve was the highest-rated quarterback in NFL history and has the distinction of being the only signal caller in league annals to win four consecutive NFL passing titles. Steve founded and chairs the Forever Young Foundation which is actively involved in children's charities worldwide and is currently the broadcast host as well as the former International Spokesperson for the Children's Miracle Network, which has raised over $1 billion dollars worldwide to benefit children's hospitals. Steve earned a J.D. from the J. Reuben Clark Law School at Brigham Young University and a B.S. in Finance and Political Science from Brigham Young University. Buy The Law of Love here: https://www.amazon.com/Law-Love-Steve-Young/dp/1639930310 Buy QB: My Life Behind the Spiral here:  https://www.amazon.com/QB-My-Life-Behind-Spiral/dp/0544845765/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=1683271315&sr=1-1 --------- Please like, subscribe, rate, and review! Every listener interaction helps others discover the show too! Learn about the work we're doing at Bravecore by visiting our website at Home - Bravecore To drop us a line, head over to Contact - Bravecore

Ep. 19 - Idera Lawal and DNA Vaccines That Work With Tattoos!

Paul Zehetmayr, LimeWire CEO, is an entrepreneur with a proven track record in business, and a background in programming and economy. Him and his brother Julian co-founded Stack Holdings, a Vienna-based SaaS portfolio company, including eversign, invoicely and ZeroSSL, used by over one million B2B customers worldwide. His previous company, apilayer, was acquired by the Texan company Idera in 2021. As the CEO of Stack Holdings, Paul not only led business development and growth, but also product development.Julian Zehetmayr, LimeWire CEO, is a founder covering business operations, market strategy and product development. He, alongside his brother Paul, is the co-founder and CEO of Stack Holdings, a company with two SaaS products: invoicely.com, eversign.com and ZeroSSL with more than one million B2B customers around the world. In 2021 he sold his company apilayer, which has a portfolio of productivity-boosting Web APIs & cloud-based microservice applications to leading Texan company Idera.In this conversation, we discuss:- The story behind the Limewire business pivot - The re-launch and repositioning of the brand - Recent private token sale - How the brand was once a major player in the media - Algorand partnership - co-CEO roles- NFTs and the music industry - How NFTs are affecting media  LimeWireWebsite: limewire.comTwitter: @limewireInstagram: @limewirePaul ZehetmayrTwitter: @PZehetmayrJulian ZehetmayrTwitter: @julianzehetmayr---------------------------------------------------------------------------------  This episode is brought to you by PrimeXBT.  PrimeXBT offers a robust trading system for both beginners and professional traders that demand highly reliable market data and performance. Traders of all experience levels can easily design and customize layouts and widgets to best fit their trading style. PrimeXBT is always offering innovative products and professional trading conditions to all customers.  PrimeXBT is running an exclusive promotion for listeners of the podcast. After making your first deposit, 50% of that first deposit will be credited to your account as a bonus that can be used as additional collateral to open positions.  Code: CRYPTONEWS50  This promotion is available for a month after activation. Click the link below:  PrimeXBT x CRYPTONEWS50

On this episode, Nicole Chikwe chats with Claire Idera Nnani; a designer, multimedia artist, mother of one and wife of actor and media personality; Akah Nnani. They talk extensively about breastfeeding and the difficulties mothers experience while at it. Nicole and Claire go on about how the efforts mothers put into giving birth and raising children are under-appreciated and how women evaluate their overall performance as mothers. Many women struggle about believing themselves to be good mothers probably due to some experiences which make them feel they failed as mothers. They also recount the rigours of childbirth and how doctors could show more empathy when dealing with pregnant women and nursing mothers. @nicolechikwe @claireidera @mumsworstdaypod @midas.radio

Resulta que al cobarde titular de MoReNa se le empareja un carro y este ya anda diciendo que lo violaron los aliens...

Juana La Plañidera

Heidi is the Head of Operations at Activtrak, a workforce analytics platform that improves team productivity. Heidi has responsibility across several functions, including HR, BI & Analytics, and Go-to-Market Operations. Previously, she served as CMO at Idera, Inc. and later as the company's General Manager for the Database Tools business where she helped acquire and integrate nearly a dozen companies.

Steve serves as Chairman of the Board of five HGGC portfolio companies: IDERA, Integrity, DealerFX, AutoAlert and Innovative.  Prior to sale, he also served as a member of the Board of Directors for the firm’s Fund II investment in Serena Software (acquired by Micro Focus International plc) and the Fund I exited investments in hybris Software (acquired by SAP SE) and Sunquest Information Systems (acquired by Roper Technologies). Prior to the inception of HGGC, Steve's professional football career spanned more than fifteen years in the NFL, primarily with the San Francisco 49ers, where he received numerous accolades, including Most Valuable Player of Super Bowl XXIX, Sports Illustrated and Sporting News' Player of the Year from 1992 - 1994 and the NFL's Most Valuable Player for 1992 and 1994. In 2005, Steve was inducted into the Pro Football Hall of Fame, the first left-handed quarterback to be so honored. When he retired, Steve was the highest-rated quarterback in NFL history and has the distinction of being the only signal-caller in league annals to win four consecutive NFL passing titles. Steve founded and chairs the Forever Young Foundation which is actively involved in children's charities worldwide and is currently the broadcast host as well as the former International Spokesperson for the Children's Miracle Network, which has raised over one billion dollars world-wide to benefit children's hospitals.

Welcome to MoEngage presents NextBigWhat: Huddle AMA Live! Remote is now the reality for many, but learning need not stop. Join us for a daily AMA with leading voices in the industry. Today we have Pallav Nadhani, Founder @ Fusioncharts - a 17-year old 100% bootstrapped (and profitable) startup and importantly, one of the few product-led global businesses from India. Fusioncharts has recently been acquired by US-based Idera and Pallav answers questions on bootstrapping, going global, building product-led business.

In this episode, you will hear Pallav Nadhani, founder of FusionCharts, one of India's longest running SaaS platforms. The company has been profitable while being entirely bootstrapped and counts some of the top companies in the world, such as Facebook, Apple and Microsoft amongs its clientele. The company has now been acquired by Idera and this is a great time to listen to this talk by Pallav given at UnPluggd Conference 2014, where he goes into the journey of bootstrapping, building a product in India, entrepreneurial lessons and much more.

stdout.fm 18번째 로그에서는 .dev 도메인, 랭킹 시각화, 개발자 설문 조사에 대해서 이야기를 나눴습니다. 참가자: @seapy, @raccoonyy, @nacyo_t Blue - Yeti TX650 디지털 보이스 레코더 TX 시리즈 | ICD-TX650 | Sony KR Blue - Yeti Nano 개발자라면 탐나는 .dev 최상위 도메인 등록 시작 | 44bits.io .DEV 도메인 이름 | .DEV 도메인 등록 - GoDaddy KR .com - 위키백과, 우리 모두의 백과사전 .io - 위키백과, 우리 모두의 백과사전 Google Registry - .dev Jon Postel - Wikipedia The TLD map with Jon Postel Wikimedia Commons ICANN - Internet Corporation for Assigned Names and Numbers Top 15 Best Global Brands Ranking (2000-2018) - YouTube Best Global Brands - Interbrand Top 10 Country GDP Ranking History (1960-2017) - YouTube Hans Rosling: 한스 로슬링이 이제껏 보지 못했던 최고의 통계를 보여준다. | TED Talk 주요 연예기획사 시가총액 순위 변화 Carmen Hernández Andoh on Twitter: “A bunch of talented, amazing people from Travis will be looking for jobs soon. … /1” IDERA | SQL Server, Database Management, and IT Performance Tools Idera acquires Travis CI | TechCrunch It looks like Ibera is gutting Travis CI just a few weeks after acquiring it : devops The Travis CI Blog: Travis CI joins the Idera family Bitrise - Mobile Continuous Integration and Delivery Continuous Integration and Delivery - CircleCI GitLab Continuous Integration & Delivery | GitLab 프로그래머스 2019 개발자 설문조사 리포트 | 프로그래머스 Python Developers Survey 2018 Results Download IntelliJ IDEA: The Java IDE for Professional Developers by JetBrains For Students: Free Professional Developer Tools by JetBrains TextMate: Text editor for macOS Bash, Zsh에서 여러줄의 명령어를 에디터로 편집하고 실행하기 | 44bits.io 셸에서 여러줄의 명령어를 에디터로 편집하고 실행하기 /w VSCode - YouTube 데이터 베이스 관리 시스템 | MySQL | Amazon Web Services Host, run, and code Python in the cloud: PythonAnywhere

Dans cet épisode, les voisins d’Arnaud ont essayé de le réduire au silence tandis qu’Antonio tentait de faire taire Audrey. Les voisins d’Arnaud ont gagné grâce à la perceuse, mais Antonio, lui, a perdu. Résultat : un épisode news où deux cast codeurs et demi discutent de l’actualité de vos languages et frameworks préférés, mais aussi de l’actualité des géants de la tech, et ça, c’est pas toujours joli. Enregistré le 8 février 2019 Téléchargement de l’épisode LesCastCodeurs-Episode–204.mp3 News Langages JDK 11.0.2 General-Availability Release + JDK 12 RC GraalVM 1.0-RC11 * GraalVM with Groovy and Grape - creating native image of a standalone script Go 1.11.5 and Go 1.10.8 are released * Un livre blanc pour démarrer en GO Frameworks Spring Framework 5.1.4, 5.0.12 and 4.3.22 available now How Fast is Spring? Et la suite : Manual Bean Definitions in Spring Boot Netflix OSS and Spring Boot — Coming Full Circle Middleware JHipster release v5.8.0 Micronaut 1.0.4 Infrastructure The future of Kubernetes is Virtual Machines L’article de Laurent Doguin sur le problème d’isolation des containers Web Node v11.8.0 Angular 7.2.0 Angular CLI 7.2 et Angular CLI 7.3 Vue 2.6 released Lightning-fast templates & Web Components: lit-html & LitElement React v16.8: The One With Hooks Google Play Store now open for Progressive Web Apps Browser diversity starts with us. Le bloqueur de pubs de Chrome va être déployé globalement Data Infinispan 10.0.0 Alpha3 and 9.4.6 final Outillage Spring Framework’s Migration from Jira to GitHub Issues Spring Boot in Visual Studio Code Travis CI joins the Idera family Jenkins crée et rejoint la Continuous Delivery Foundation au sein de la Linux Foundation GitLab 11.7 Gradle 5.2 Sécurité Google DNS Service (8.8.8.8) Now Supports DNS-over-TLS Security Loi, société et organisation Oracle v. Google and the future of software development AWS vs l’Open Source, la suite AWS gives open source the middle finger AWS, MongoDB, and the Economic Realities of Open Source Première amende pour non conformité au RGPD, de 50 millions d’euros à l’encontre de Google Premiere sanction contre Google suite à nos plaintes collectives La formation restreinte de la CNIL prononce une sanction de 50 millions d’euros à l’encontre de la société GOOGLE LLC Facebook continue à se distinguer … Zuckerberg Plans to Integrate WhatsApp, Instagram and Facebook Messenger Apple says it’s banning Facebook’s research app that collects users’ personal information Facebook paid people to gather data on usage habits … et il n’est pas le seul : Google will stop peddling a data collector through Apple’s back door Article 13 is back on – and it got worse, not better Conférences DevFest Du Bout du Monde le 22 février 2019 ConFoo Montreal 2019 du 13 au 15 Mars 2019 Breizh Camp du 20 au 22 mars 2019 Greach (Madrid) du 28 au 30 Mars 2019 Devoxx France du 17 au 19 avril 2019 - sold out VoxxedCERN le 1er mai 2019 Riviera Dev du 15 au 17 mai 2019 NCrafts les 16 et 17 mai 2019 Mix-it les 23 et 24 mai 2019 BestOfWeb les 6 et 7 juin 2019 DevFest Lille le 14 juin 2019 - Le CfP est ouvert. Voxxed Days Luxembourg les 20 et 21 juin 2019 - le CfP est ouvert. Sunny Tech les 27 & 28 juin 2019 à Montpellier - Le CfP est ouvert. Nous contacter Soutenez Les Cast Codeurs sur Patreon https://www.patreon.com/LesCastCodeurs Faire un crowdcast ou une crowdquestion Contactez-nous via twitter https://twitter.com/lescastcodeurs sur le groupe Google https://groups.google.com/group/lescastcodeurs ou sur le site web https://lescastcodeurs.com/  

Episode 8  – Now With Insane Magic This week we talk about TLS support for NLB, AWS Worklink, Kubernetes Metering and retailers pushing back on AWS. Plus the lightning round and cool tools with Jonathan. #thecloudpod Thanks to our Sponsors: Foghorn Consulting: fogops.io/thecloudpod Audible: audibletrial.com/thecloudpod News Microsoft Earnings – http://fortune.com/2019/01/30/microsoft-stock-down-slowdown-azure-cloud/ Idera acquires Travis CI – https://techcrunch.com/2019/01/23/idera-acquires-travis-ci/ Google Gives Wikipedia Millions – https://www.wired.com/story/google-wikipedia-machine-learning-glow-languages/ NLB now supports TLS Termination – https://aws.amazon.com/blogs/aws/new-tls-termination-for-network-load-balancers Microsoft Acquires Citus Data – https://blogs.microsoft.com/blog/2019/01/24/microsoft-acquires-citus-data-re-affirming-its-commitment-to-open-source-and-accelerating-azure-postgresql-performance-and-scale/ AWS Worklink secures on premise website and apps – https://aws.amazon.com/blogs/aws/amazon-worklink-secure-one-click-mobile-access-to-internal-websites-and-applications/ GKE Usage Metering https://cloud.google.com/blog/products/containers-kubernetes/gke-usage-metering-whose-line-item-is-it-anyway Albertsons picks Azure to run cloud workloads due to Amazon being a competitor – https://www.fool.com/investing/2019/01/28/amazon-fear-is-driving-retailers-to-microsofts-clo.aspx Lightning Round Python Shell for AWS Glue – https://aws.amazon.com/about-aws/whats-new/2019/01/introducing-python-shell-jobs-in-aws-

Show: 383 Description: Aaron and Brian talk with Paul D. Johnston (@PaulDJohnston, Co-Founder ServerlessDays (creator of “Jeff”), CXO Serverless Consultant) about the current state of Serverless, Serverless vs. FaaS, how to economically think about functions of code, and areas where Serverless needs to improve. Show Sponsor Links:Datadog Homepage - Modern Monitoring and AnalyticsTry Datadog yourself by starting a free, 14-day trial today. Listeners of this podcast will also receive a free Datadog T-shirtLiquid Technology - IT Value RecoveryTry CloudLast Service, get a free t-shirt and chance at Amazon Gift CardCloud News of the WeekIBM signs deal with Vodafone - https://newsroom.ibm.com/2019-01-17-IBM-Vodafone-Business-Join-Forces-to-Drive-Innovation-in-Rapidly-Changing-WorldIBM signs deal with Juniper - https://www.ibm.com/blogs/cloud-computing/2019/01/18/ibm-juniper-cloud-agreement/Travis CI acquired by Idera - https://blog.travis-ci.com/2019-01-23-travis-ci-joins-idera-incConfluent, creators of Kafka, raised $125M in VC funding in a Round D, at a $2.5B valuation - https://www.forbes.com/sites/alexkonrad/2019/01/23/open-source-unicorn-confluent-reaches-25-billion-valuation-three-years-after-hiring-its-first-sales-rep/#67d93c3315e2Microsoft buys Citus Data (open source Postgres SQL) - http://zd.net/2FQfF2vShow Interview Links:Paul’s Blog - https://medium.com/@PaulDJohnstonThe ServerlessCast #6 - Event-Driven Thinking with Paul Johnson - http://www.thecloudcast.net/2017/05/the-serverlesscast-6-events-vs-functions.htmlServerlessDays - https://serverlessdays.io/Show Notes:Topic 1 - Happy New Year, hope you’re having a good 2019. It’s been a while since you were last on the show. As the creator of Jeff, what have you been up to lately?Topic 2 - Let’s talk about a basic thing that seems to confuse people. What’s the new definition, or the actual difference (if there is any), between “Serverless” and “Functions as a Service”. Topic 3 - I’ve seen you mention several times on Twitter that, “Few people really understand how powerful serverless can be. They focus on the wrong things.” Help us get focused on the important parts. Topic 4 - I’ve also seen you say that “with serverless, infrastructure is a rounding error.” Walk us through the economics of your experiences with serverless, and how you think about “profitable software”.Topic 5 - Why do you think it seems like so many of the other cloud offerings are so far behind AWS Lambda? Topic 6 - At a high level, what is working well in serverless, and what is still complicated or missing? What’s your wishlist for 2019?Feedback?Email: show at thecloudcast dot netTwitter: @thecloudcastnet and

Coté has a late night, mental breakdown about scorecards. Can Brandon save him? Also, kafka, Travis CI, and snow. Relevant to your interests Atlassian surpassed $1B in calendar-year revenue in 2018 (https://www.zdnet.com/article/atlassian-surpassed-1b-in-calendar-year-revenue-in-2018/) Google remains the top open-source contributor to CNCF projects (https://techcrunch.com/2019/01/17/google-remains-the-top-open-source-contributor-to-cncf-projects/) Oracle exec: Open-source vendors locking down licences proves 'they were never really open (https://www.theregister.co.uk/2019/01/17/oracle_exec_opensource_vendors_locking_down_licenses_proves_they_were_never_really_open/)’ Morgan Stanley Downgrades Oracle Stock on Dim Growth Prospects (https://www.barrons.com/articles/oracle-stock-morgan-stanley-downgrades-51547572633) Vodafone signs $550m deal with IBM to offload cloud biz (https://www.theregister.co.uk/2019/01/18/vodafone_signs_550m_deal_with_ibm_to_offload_cloud_biz/) Insiders say that Google's new cloud boss is likely to make some very large acquisitions (https://www.businessinsider.com/new-google-cloud-ceo-thomas-kurian-acquisitions-2019-1) 'The goal is to automate us': welcome to the age of surveillance capitalism (https://www.theguardian.com/technology/2019/jan/20/shoshana-zuboff-age-of-surveillance-capitalism-google-facebook) Just forget what Gartner said about AI in June 'cos CIOs are all over it now apparently (http://go.theregister.com/feed/www.theregister.co.uk/2019/01/21/gartner_ai_cio_research/) Open-Source Unicorn: Confluent Reaches $2.5 Billion Valuation Three Years After Hiring Its First Sales Rep (https://www.forbes.com/sites/alexkonrad/2019/01/23/open-source-unicorn-confluent-reaches-25-billion-valuation-three-years-after-hiring-its-first-sales-rep/) Travis CI joins the Idera family (https://blog.travis-ci.com/2019-01-23-travis-ci-joins-idera-inc) IBM Boasts Another Big Win, Touts Hybrid Cloud Prowess (https://www.sdxcentral.com/articles/news/ibm-boasts-another-big-win-touts-hybrid-cloud-prowess/2019/01/?utm_source=feedblitz&utm_medium=FeedBlitzRss&utm_campaign=sdxcentral) Microsoft wins cloud business from Albertsons as fear of Amazon grows among retailers (https://www.cnbc.com/2019/01/23/microsoft-signs-cloud-deal-with-albertsons.html) Non Sense Oreo Competitor Makes Federal Case Out of ‘Cutthroat’ Cookie Rivalry (https://www.wsj.com/articles/food-fight-in-the-cookie-aislehydrox-vs-oreo-turns-cutthroat-11547740235) ROAD TRIP! Buc-ee's opens 1st location outside of Texas (https://abc13.com/business/road-trip-buc-ees-opens-1st-location-outside-of-texas/5099836/) Sponsors Solarwinds To learn more or try the company’s DevOps products for free, visit https://solarwinds.com/devops. Arrested DevOps Subscribe to the Arrested DevOps podcast by visiting https://www.arresteddevops.com/ Conferences, et. al. ALERT! DevOpsDays Discount - DevOpsDays MSP (https://www.devopsdays.org/events/2019-minneapolis/welcome/), August 6th to 7th, $50 off with the code SDT2019 (https://www.eventbrite.com/e/devopsdays-minneapolis-2019-tickets-51444848928?discount=SDT2019). 2019, a city near you: The 2019 SpringTours are posted (http://springonetour.io/). Coté will be speaking at many of these, hopefully all the ones in EMEA. They’re free and all about programming and DevOps things. Free lunch and stickers! Jan 28th to 29th, 2019 - SpringOne Tour Charlotte (https://springonetour.io/2019/charlotte), $50 off with the code S1Tour2019_100. Feb 12th to 13th, 2019 - SpringOne Tour St. Louis (https://springonetour.io/2019/st-louis). $50 off the code S1Tour2019_100. Mar 7th to 8th, 2019 - Incontro DevOps in Bologna (https://2019.incontrodevops.it/), Coté speaking. Mar 13th, 2019 - Coté speaking at (platform as a product) (https://www.meetup.com/Continuous-Delivery-Amsterdam/events/258120367/) - Continuous Delivery, Amsterdam. Mar 18th to 19th, 2019 - SpringOne Tour London (https://springonetour.io/2019/london). Get £50 off ticket price of £150 with the code S1Tour2019_100. Mar 21st to 2nd, 2019 (https://springonetour.io/2019/amsterdam) - SpringOne Tour Amsterdam. Get €50 off ticket price of €150 with the code S1Tour2019_100. Get a Free SDT T-Shirt Write an iTunes review of SDT and get a free SDT T-Shirt. Write an iTunes Review on the SDT iTunes Page. (https://itunes.apple.com/us/podcast/software-defined-talk/id893738521?mt=2) Send an email to stickers@softwaredefinedtalk.com (mailto:stickers@softwaredefinedtalk.com) and include the following: T-Shirt Size (Only Large or X-Large remain), Preferred Color (Gray, Black) and Postal address. First come, first serve. while supplies last! Can only ship T-Shirts within the United State SDT news & hype Join us in Slack (http://www.softwaredefinedtalk.com/slack). Follow us on Twitter (https://twitter.com/softwaredeftalk), Instagram (https://www.instagram.com/softwaredefinedtalk/) or LinkedIn (https://www.linkedin.com/company/software-defined-talk/) Send your postal address to stickers@softwaredefinedtalk.com (mailto:stickers@softwaredefinedtalk.com) and we will send you a sticker. Listen to the Software Defined Interviews Podcast (https://www.softwaredefinedinterviews.com/). Check out the back catalog (http://cote.coffee/howtotech/). Brandon built the Quick Concall iPhone App (https://itunes.apple.com/us/app/quick-concall/id1399948033?mt=8) and he wants you to buy it for $0.99. Recommendations Brandon: (https://www.audible.com/pd/Billion-Dollar-Whale-Audiobook/1478948000?qid=1548351044&sr=1-1&ref=a_search_c3_lProduct_1_1&pf_rd_p=e81b7c27-6880-467a-b5a7-13cef5d729fe&pf_rd_r=D3A67G0APYVG06H98NGK&)Billion Dollar Whale (https://www.audible.com/pd/Billion-Dollar-Whale-Audiobook/1478948000?qid=1548351044&sr=1-1&ref=a_search_c3_lProduct_1_1&pf_rd_p=e81b7c27-6880-467a-b5a7-13cef5d729fe&pf_rd_r=D3A67G0APYVG06H98NGK&), Malaysia Wants Goldman’s Money Back (https://www.bloomberg.com/opinion/articles/2019-01-18/malaysia-wants-goldman-s-money-back). Coté: UNIQLO HEATTECH (https://www.uniqlo.com/uk/en/men/featured/heattech), as soft as a fancy conference t-shirt. Herbarium (https://www.ceskatelevize.cz/telexport/programmes?kategorie=24&porad=770), dubbed in English - “that’s Jim’s spatula!” Outro: "'93 'til Infinity." (https://genius.com/Souls-of-mischief-93-til-infinity-lyrics)

In this episode of our Six Weeks to Fitness podcast, I am joined by Mrs. Idera Abdullah (“Sister Bisi”), Founder and Executive Director of IMANI HOUSE, Inc., a 501(c)(3) nonprofit organization, serving marginalized youth, families, and immigrants in Brooklyn, NY, and Liberia, West Africa.   During the interview, Sister Bisi will share her motivation for creating Imani House. With programs ranging from literacy and job readiness classes for adults, to after-school programs and camps for children, Imani House continues to accomplish great things with the vision and hard work of Sister Bisi as its driving force.  Also in the interview, Sister Bisi will discuss the work Imani House is doing to address the epidemic of childhood obesity, through their upcoming 6th Annual “Walk to Live Walk-A-Thon and Festival,” which will take place on June 2nd from 9:30am to 3pm, at the Grecian Shelter in Prospect Park, entrance at Parkside Ave and Parade Place.  One of Imani House’s missions is to “help people do for themselves,” and walking, Sister Bisi believes, is one of the best exercises you can do for yourself.  It doesn’t’ cost you anything but it can improve your health significantly and that’s how it started for Sister Bisi.  She was once very overweight and when a friend initially invited her to participate in a walk, she tried and failed but that didn’t stop her from continuing to try.  On her third attempt at walking around the park, she succeeded and became an avid walker ever since.  Sister Bisi knows what walking can do to improve your health.  Sister Bisi noted that too many kids today are suffering from diabetes and high blood pressure due to lack of inactivity and poor eating habits.  This is more prevalent among black and Latino kids.  The 6th Annual Walk to Live Walk-A-Thon and Festival was created to bring communities together and bring awareness to this very serious issue before it gets worse.   Following the 3.5-mile walk, there will be various types of fun activities, including music, dancing, games and prizes.  There will also be healthy snacks and visits from local politicians.  All are welcome to attend. For more information about participating, volunteering, or supporting Walk-to-Live, please visit www.ihiwalktolive.com, email imani@imanihouse.org, or call (718) 638-2059.  This was a very inspiring interview.  I hope to see you at the Walk!

Hola a todas y a todos y bienvenidos una vez más a Ohhh! TV Podcast. Estrenamos nueva temporada, la 11, o lo que viene a ser, nuestro programa 223. En este episodio haremos un repaso de varios pilotos que hemos visto, entre ellos: Atlanta Better things Designated survivor Son of Zorn The good place Pitch … Continuar leyendo "s11e01: La gruñidera"

Today in FirstWord:

Starring:Host: Robbie FergusonCo-Host: Sasha Dirmeitis On our cosplay special, Robbie and Sasha reveal a feature-packed backup tool from Idera: the same people who brought us Linux HotCopy. Read the complete show notes, comment or rate this episode, view pictures and obtain links from this episode at https://category5.tv/shows/technology/episode/319/ Running time: 1 Hour 1 Minute 26 Seconds

Richard Giles from Idera on PowerShell Plus

Parind Shah from Dell on EqualLogic and their new PowerShell module!   News This segment is brought to you by Start-Automating   Start Scripting to Your Fullest Potential.  At Start-Automating, we can help you unleash the full Power of PowerShell V2.  You can use our deep PowerShell expertise to build rich PowerShell solutions, or we can train you to use PowerShell like a pro. Isn’t it time you Save-Time, Save-Money, and Start-Automating?  Find out more at Start-Automating.com.   Marc van Orsouw will be running the PowerShell Script Club in Zurich Feb 1st Don Jones is seeking input on his upcoming advanced-level PowerShell book. Leave your comments on his blog! PowerWF celebrates a new release: 2.4 just shipped and includes PowerSE, a "Script Editor, console, intellisense, and powerful debugger" Idera ships PowerShell Plus v4 beta! New to us, /n Software released PowerShell eXplorer to the iTunes Market for IOS devices Interview The news is brought to you by Don Jones' 2011 PowerShell Retreat in Las Vegas   Links:   http://www.equallogic.com/ http://virtualisedreality.com/2010/12/17/dell-equallogic-powershell-quick-reference-guide/ http://delltechcenter.com/   Chatroom Buzz: 21:47 ##when is storage monitoring coming to PowerShell? 21:49 ## have your tried to get a consistent PowerShell story with other SAN manufacturers like Compellent? 21:54 # was the top-down part of the push for PowerShell management part of an overall push @ dell?  There are a lot of dell hardware that could use specialized management 21:54 # what do you have in mind for the 2nd release? 22:08 right now there are 13 pages of jobs of PowerShell on LinkedIn 23:44 @ joel, sure, but debug/verbose/warning are the lamest of all streams Superhero: Software X-Ray Vision aka The Debugger aka BugBuster aka RAID! Resources   This segment is brought to you by SAPIEN Technologies   Windows PowerShell Survival Guide Create DNS PTR records from PowerShell James Brundage made a cool add-on for PowerGUI to control advanced PowerShell options Jaykul writes about using parentheses in PowerShell The Scripting Guys have an article on parsing the event log using Get-WinEvent Aaron Nelson has been posting PowerShell Week at SQL University info. More about SQL University is at SQLChicken.com Don Jones has a bunch of PowerShell videos on his YouTube channel!   Tips This segment brought to you by ServerFault.com   From Ravi: Use Dropbox to share profiles across multiple systems Get your logging on: Oisin's script logger module Jaykul's NLog module Doug Finke's PSLog (also an NLog wrapper) Log4Posh: PowerShell Log4Net wrapper What the heck is Finally for? (as in Try..Catch..Finally) Clear an AD attribute   One-Liner of the Week! Get-Service | Add-Member ScriptMethod ToString { $this.Name } -Force -PassThru | Group-Object StatusAnd here is the PS1XML version

I met Susan on Saltspring Island where she now lives. She worked in a high school in the Lay Congo Mission. She served with SUCO and worked with CUSO in the BC office from 1984-1986 as teh BC Coordinator. Volunteer for a better world! Join CUSO-VSO, share skills and volunteer in 43 countries in Africa, Asia, the Pacific, Latin America and the Caribbean. Volunteers, donate, share skills.www.cuso-vso.org